STS数据库:肺叶切除与亚肺叶切除比较——患者因素与淋巴结评估的重要性
基于STS前瞻性数据库链接Medicare生存数据,纳入20031例≤2cm cT1N0非小细胞肺癌患者,比较肺叶切除与亚肺叶切除的生存。亚肺叶切除组淋巴结采样更少(平均5.5 vs 12.8),病理升期更少(7.1% vs 14.2%)。在≥75岁、FEV1 10%-59%、Zubrod 2-3分组中两种切除生存相似;亚肺叶切除若淋巴结评估不足(<2枚)则生存劣于肺叶切除。
要点
- ≤2cm cT1N0 NSCLC中,高龄或体能状态较差者亚肺叶切除与肺叶切除生存相似。
- 亚肺叶切除需保证足够淋巴结评估(至少2枚),否则生存劣于肺叶切除。
- 淋巴结升期患者中,肺叶切除未显示生存优于亚肺叶切除。
核心结论
- 在真实世界中,对于高龄或健康状况较差的患者,只要进行充分的淋巴结切除,亚肺叶切除可获得与肺叶切除相似的生存。
- 淋巴结升期时行肺叶切除并未明显改善生存。
研究设计与样本
- 基于STS前瞻性数据库链接Medicare生存数据,采用概率匹配算法。
- 共纳入20031例≤2cm、淋巴结阴性(cT1N0)非小细胞肺癌患者。
- 其中肺叶切除11976例,肺段切除2586例,楔形切除5469例。
- 采用倾向评分加权Kaplan-Meier分析评估生存。
主要发现
- 亚肺叶切除组淋巴结采样数少于肺叶切除组(平均5.5 vs 12.8)。
- 亚肺叶切除组病理升期比例低于肺叶切除组(7.1% vs 14.2%)。
- 在年龄≥75岁(P = .07)、FEV1 10%-59%(P = .14)、Zubrod体能状态2-3(P = .23)的亚组中,亚肺叶切除与肺叶切除的总生存相似。
- 亚肺叶切除时若淋巴结评估不足(切除<2枚淋巴结),生存劣于肺叶切除(P < .001)。
- 在淋巴结升期患者中,肺叶切除与亚肺叶切除的生存无显著差异(P = .42)。
临床怎么用
- 对高龄或心肺功能较差、体能状态欠佳的≤2cm cT1N0 NSCLC患者,可考虑亚肺叶切除。
- 行亚肺叶切除时必须保证充分的淋巴结采样(至少2枚淋巴结),以避免生存受损。
- 若术后发现淋巴结升期,无需因升期而常规追加肺叶切除,因肺叶切除未显示生存优势。
局限性
- 研究为回顾性数据库分析,可能存在选择偏倚和未测量混杂因素。
- 淋巴结评估不足的定义为切除<2枚淋巴结,可能低估更广泛采样的人群。
- 需进一步研究明确亚肺叶切除在一般人群中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prospective randomized trials have demonstrated noninferior survival between sublobar resection and lobectomy in healthy patients with non-small cell lung cancer with tumors ≤2 cm. However, some patient attributes are not well represented in randomized trials, and uncertainty remains in the widespread applicability of randomized trial nodal dissection protocols. METHODS: Patients with ≤2 cm, node-negative non-small cell lung cancer (cT1 N0) in The Society of Thoracic Surgeons prospective database were linked to Medicare survival data by using a probabilistic matching algorithm. Survival was assessed by propensity score-weighted Kaplan-Meier analysis. RESULTS: Overall, 20,031 patients were identified, including 11,976 patients who underwent lobectomy, 2586 who underwent segmentectomy, and 5469 who underwent wedge resection. Fewer lymph nodes were sampled in the sublobar resection group (mean, 5.5 vs 12.8), and pathologic upstaging was less common (7.1% vs 14.2%). Overall survival after sublobar and lobar resection was similar within groups understudied in recent trials, including age ≥75 years (P = .07), forced expiratory volume in 1 second of 10% to 59% (P = .14), and Zubrod performance status 2 to 3 (P = .23). When sublobar resection was performed with inadequate nodal evaluation (<2 nodes removed), survival was inferior to survival after lobectomy (P < .001). Among patients with nodal upstaging, lobectomy was not associated with improved survival over sublobar resection (P = .42). CONCLUSIONS: The clinical trial finding that sublobar resections achieve survival similar to that seen with lobectomy in early-stage lung cancer appears to apply to older, less healthy patients in a real-world setting, provided adequate lymph node resection is performed. Performing a lobectomy in the setting of nodal upstaging does not obviously improve survival. Further study is warranted to clarify the role of sublobar resection in the general population.
引用
- Woodard GA, Grau-Sepulveda M, Onaitis MW, et al. Lobectomy vs Sublobar Resection in The Society of Thoracic Surgeons Database: Importance of Patient Factors and Lymph Node Evaluation. Ann Thorac Surg. 2025. PMID: 39864772. doi:10.1016/j.athoracsur.2025.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。